Catalog No.
DHC21902
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-nd
Clonality
Monoclonal
Target
MSK8, VNRA, Vitronectin receptor, Integrin alpha-V, Vitronectin receptor subunit alpha, CD51, ITGAV, VTNR, GPIIIa, Integrin beta-3, CD61, ITGB3, Platelet membrane glycoprotein IIIa, GP3A
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P06756 & P05106
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
MEDI-522, hLM60, CAS: 892553-42-3
Clone ID
Etaracizumab
Pharmacodynamic (phase 0) study using etaracizumab in advanced melanoma, PMID: 20445352
A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma, PMID: 20108344
Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors, PMID: 17876527
Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer, PMID: 18953435
Combined anti-angiogenic therapy against VEGF and integrin alphaVbeta3 in an orthotopic model of ovarian cancer, PMID: 19829059
Gateways to clinical trials, PMID: 17805439
Gateways to clinical trials, PMID: 21069103
Vitaxin applied molecular evolution, PMID: 11249574
Integrins: molecular targets in cancer therapy, PMID: 16507218
A reevaluation of integrins as regulators of angiogenesis, PMID: 12205444
Metastatic melanoma - a review of current and future drugs, PMID: 24432031
Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism, PMID: 17017851
[Recent progress in clinical trials with antimetastatic drugs], PMID: 10553408
Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases, PMID: 12379637
[Research on the antimetastatic agents], PMID: 16201504
Integrin alphavbeta3-targeted radioimmunotherapy of glioblastoma multiforme, PMID: 19010848
The role of alpha(v)beta3 integrins in vascular healing, PMID: 11858476
The Therapeutic Antibody LM609 Selectively Inhibits Ligand Binding to Human α V β 3 Integrin via Steric Hindrance, PMID: 29033288
Snake venom protein paralyzes cancer cells, PMID: 11181769
Targeting angiogenesis with antibodies for the treatment of cancer, PMID: 16118694
Specific targeting of human integrin α(v)β (3) with (111)In-labeled Abegrin™ in nude mouse models, PMID: 20383594
Direct targeting of alphavbeta3 integrin on tumor cells with a monoclonal antibody, Abegrin, PMID: 17172415
Effects of Vitaxin, a novel therapeutic in trial for metastatic bone tumors, on osteoclast functions in vitro, PMID: 17390341
Pilot study of vitaxin--an angiogenesis inhibitor-in patients with advanced leiomyosarcomas, PMID: 11571751
In vitro and in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alpha v beta 3, PMID: 17018625
Modeling and analysis of protein design under resource constraints, PMID: 15767779
Increased flow precedes remote arteriolar dilations for some microapplied agonists, PMID: 10749713
Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3, PMID: 10955784
Stepwise in vitro affinity maturation of Vitaxin, an alphav beta3-specific humanized mAb, PMID: 9600913
Monoclonal antibodies to alphaVbeta3 (7E3 and LM609) inhibit sickle red blood cell-endothelium interactions induced by platelet-activating factor, PMID: 10627437
Asthma remission in a patient with rheumatoid arthritis while on antiangiogenesis therapy during a rheumatoid arthritis trial demonstrated by forced oscillation and spirometry, PMID: 17530526
A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer, PMID: 11385959
Vitaxin, a humanized monoclonal antibody to the vitronectin receptor (alphavbeta3), reduces neointimal hyperplasia and total vessel area after balloon injury in hypercholesterolemic rabbits, PMID: 10364564
MedImmune initiates phase I/II clinical study with Vitaxin, PMID: 12113018
For research use only. Not for human or drug use.
